Life Recovery Systems
OperatingLIFE RECOVERY SYSTEMS HD LLC
Biotech · Alexandria, LA
Financials
FY2015–FY2018 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Fundraising history
Team
10 people
Is the co-founder, co-inventor, Chairman of the Board of Directors and Chief Medical and Strategy Officer. He is an interventional cardiologist, was a Flight Surgeon trained at the U.S. Air Force School of Aerospace Medicine and trained in Cardiology at The University of Texas Health Science Center in Houston. Over the last three years (2015-2018) Dr. Freedman has served as Chairman of the Board of Managers and Chief Medical Officer of Life Recovery Systems, LLC, working out of its business office in Alexandria, LA. During that time he has also served as Manager of Freedman Memorial Cardiology in Alexandria, LA.
The co-founder, co-inventor and Vice President of Research & Development. He received a Ph.D. in Biomedical Engineering from Rensselaer Polytechnic Institute and has over 20 years of experience leading R&D groups in cardiac assist, critical care and anesthesia. Previously he managed an R&D Group in Critical Care and Anesthesia for Mallinckrodt Pharmaceutical. Over the last three years (2015-2018) Dr. Schock has served as Vice President of Research and Development of Life Recovery Systems, LLC, working out of its Research and Manufacturing facility in Kinnelon, NJ.
Is the Vice President of Operations. He has over 30 years of experience in Pharmaceutical R&D, Medical Device Quality Assurance, Regulatory and Clinical Affairs. He has held positions at Sandoz Pharmaceuticals, C.R. Bard and Ackrad Laboratories. Over the last three years Mr. Hettenbach has served as Vice President of Operations of Life Recovery Systems, LLC in its Kinnelon, NJ office. Over that same period he has also worked as a Regulatory Affairs consultant in his private consulting company, Medqra, LLC, which is based in Morris Plains, NJ.
is the Financial Manager. He is a CPA and a retired Principal in Knight Masden, a professional accounting corporation based in Alexandria, LA. He was one of the original founders of the accounting firm and served in management for 34 years before retirement in 2004 He has assisted Life Recovery Systems from 2005 to 2018 as a financial consultant.
Retired after 37 years from private invasive cardiology practice in Lafayette, Louisiana. Former Board Member of two general hospitals and one cardiovascular specialty hospital. Served on the Life Recovery Systems Board of Managers from February 1, 2015 to the present.
President, GRITS Entities, LLC Back Office Support September, 2017 - Present Producer, On Point Talk Television Television Talk Show May, 2014 - Present Served on the Life Recovery Systems Board of Managers From February 1, 2015 to the present.
Co-owner and Vice-President of Kilpatrick Life Insurance Companies and Rose-Neath Funeral Homes, Crematorium and Cemeteries and Flower Shop 1976-Present Served on the Life Recovery Systems Board of Managers from February 1, 2015 to the present
Show 1 more personShow fewer
President, Central Louisiana Anesthesia & Pain Management Ctr. October 1, 1995 to present. Secretary, Central Louisiana Surgical Hospital January 1, 2016 - December 31, 2018 Served on the Life Recovery Systems Board of Managers from February 1, 2015 to the present.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 9 annual reports (FY2017–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 10 filings on EDGAR- Form C-UMay 22, 20190001665160-19-000658EDGAR
- Form C-UMay 8, 20190001665160-19-000628EDGAR
- Form C-ARApr 30, 20190001665160-19-000543EDGAR
- Form C-UNov 6, 20180001665160-18-001192EDGAR
- Form C/AAug 30, 20180001665160-18-000876EDGAR
- Form C/AJun 28, 20180001665160-18-000631EDGAR
- Form C/AMay 4, 20180001665160-18-000416EDGAR
- Form C/AMar 26, 20180001665160-18-000241EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.